Löscher W, Vetter M
Biochem Pharmacol. 1985 May 15;34(10):1747-56. doi: 10.1016/0006-2952(85)90645-8.
A newly developed synaptosomal model was used to evaluate the in vivo effects of the GABA-elevating drugs aminooxyacetic acid (AOAA, 30 mg/kg i.p.) and valproic acid (VPA, 200 mg/kg i.p.) on GABA levels in nerve endings of 11 brain regions in rats as a function of time after administration. The data obtained were compared with the magnitude and time course of the effects of both drugs in rats on body temperature, pain response and against seizures induced by electroshock, pentylenetetrazol and 3-mercaptopropionic acid. Following AOAA, maximum increases in synaptosomal GABA levels of brain regions were observed 6 hr after administration. At this time, GABA was significantly elevated up to 300% over control values in synaptosomal fractions from all 11 regions. However, the hypothermic and antinociceptive effects of the drug as well as its anticonvulsant action against electroshock and pentylenetetrazol induced seizures were maximal 1 hr after injection and had vanished after 6 hr, i.e. at the time of maximum GABA increases in synaptosomes. The only pharmacological effect of AOAA which paralleled the time course of the synaptosomal GABA elevation was the attenuation of seizures induced by 3-mercaptopropionic acid. Following VPA, the effect on synaptosomal GABA levels was much more rapid in onset and significant increases were already determined 5 to 30 min after administration. Significant increases of up to 80% over control values were found in synaptosomal fractions from olfactory bulb, frontal cortex, hippocampus, hypothalamus, tectum, substantia nigra and cerebellum. In contrast to AOAA, the time course of the synaptosomal GABA increases, at least in some regions, was similar to the time course of VPA's antinociceptice effects and its anticonvulsant effects in the three seizure models studied. The data may suggest that AOAA and VPA increase different pools of GABA within nerve terminals, only one of which is involved in GABA-mediated neurotransmission.
一种新开发的突触体模型被用于评估提高γ-氨基丁酸(GABA)的药物氨氧基乙酸(AOAA,腹腔注射30mg/kg)和丙戊酸(VPA,腹腔注射200mg/kg)对大鼠11个脑区神经末梢中GABA水平随给药后时间的变化的体内效应。将获得的数据与这两种药物对大鼠体温、疼痛反应以及对电休克、戊四氮和3-巯基丙酸诱导的癫痫发作的作用强度和时间进程进行比较。给予AOAA后,给药6小时后观察到脑区突触体GABA水平的最大升高。此时,所有11个区域的突触体组分中GABA比对照值显著升高达300%。然而,该药物的低温和抗伤害感受作用以及其对电休克和戊四氮诱导的癫痫发作的抗惊厥作用在注射后1小时最大,并且在6小时后消失,即在突触体中GABA最大增加时。AOAA唯一与突触体GABA升高时间进程平行的药理作用是对3-巯基丙酸诱导的癫痫发作的减轻。给予VPA后,对突触体GABA水平的作用起效更快,给药后5至30分钟已确定有显著增加。在嗅球、额叶皮质、海马、下丘脑、顶盖、黑质和小脑的突触体组分中发现比对照值显著增加高达80%。与AOAA相反,至少在某些区域,突触体GABA增加的时间进程与VPA在研究的三种癫痫模型中的抗伤害感受作用及其抗惊厥作用的时间进程相似。数据可能表明AOAA和VPA增加神经末梢内不同的GABA池,其中只有一个参与GABA介导的神经传递。